*** Open to All ***
GLP-1 therapies have rapidly shifted from niche diabetes treatments to high-demand metabolic medications—with utilization, expectations, and spend accelerating just as quickly. For benefit managers and self-funded employers, the question is no longer whether to address GLP-1s—but how.
This session will examine the clinical evidence, utilization trends, and long-term outcomes driving demand, while unpacking the real financial implications for self-funded health plans. We’ll analyze cost trajectories, adherence patterns, discontinuation risk, and the downstream impact on claims, stop-loss exposure, and workforce productivity.
This is a candid, data-driven discussion designed for decision-makers balancing fiduciary responsibility with employee health outcomes. Walk away with a strategic framework to determine whether GLP-1 coverage is a catalyst for long-term value—or a looming financial liability.
Speakers:
***********************
Pending approval for 2.0 Hours of SHRM and HRCI CE